Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion type Assertion NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_head.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion wasGeneratedBy ECO_0000203 NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_provenance.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion wasDerivedFrom befree-20140225 NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_provenance.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion SIO_000772 17297461 NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_provenance.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion evidence source_evidence_literature NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_provenance.
- NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_assertion description "[CpG methylation-dependent silencing of SFRP1, SFRP2 and SFRP5 was frequently seen among GC cell lines (SFRP1, 16/16, 100%; SFRP2, 16/16, 100%; SFRP5, 13/16, 81%) and primary GC specimens (SFRP1, 42/46, 91%; SFRP2, 44/46, 96%; SFRP5, 30/46, 65%), and treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine rapidly restored SFRP expression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP174521.RAeMO98L1rNv_aqVNoi25585LWU0MsOmSLlrAEZmSGu6s130_provenance.